Treatment Sequencing and Alternative Therapies

Dr. Bouberhan explores first-line treatment approaches for metastatic disease, asking whether nab-sirolimus represents standard initial therapy based on FDA approval and AMPECT trial results. Dr. Choy confirms current practice favors nab-sirolimus as first-line therapy, contrasting this with historical approaches using conventional chemotherapy with 10% to 20% response rates, immunotherapy drugs like pembrolizumab achieving similar response ranges, or VEGF inhibitors such as pazopanib with approximately 10% response rates.

The superior tolerability profile of nab-sirolimus influences treatment sequencing decisions. Given minimal side effects compared to conventional chemotherapy, nab-sirolimus offers easier first-line administration even for patients unlikely to demonstrate optimal responses. For non-TSC2 patients with 13% response rates, nab-sirolimus toxicity remains preferable to harsher chemotherapy regimens, making initial trial reasonable before progressing to alternative agents.

Treatment selection strategy remains straightforward: nab-sirolimus represents optimal first-line therapy for metastatic disease regardless of molecular subtype, followed by sequential alternative therapies including conventional chemotherapy, immunotherapy, or VEGF inhibitors as subsequent lines for fit patients with continued treatment candidacy.

Dr. Bouberhan reviews immunotherapy literature for patients with tumors lacking TSC1/TSC2 mutations. Memorial Sloan Kettering retrospective analysis of 13 patients with advanced PEComas from various anatomical sites treated with physician-choice immunotherapy (single-agent pembrolizumab, nivolumab, or combination regimens) demonstrated 23% objective response rates with two patients achieving durable responses exceeding 18 months. A single patient with TFE3 fusion-positive tumor achieved objective response to immune checkpoint inhibition.

The DART-SWOG S1609 trial cohort 38 investigated ipilimumab plus nivolumab combination in patients with PEComa, reporting 19% objective response rates, though notably excluding TFE3 fusion-positive tumors from this cohort. These findings support meaningful immunotherapy activity within the 10% to 20% response range, validating alternative treatment options while highlighting the need for optimal treatment identification in patients whose tumors demonstrate less mTOR pathway dependence.

Some patients achieve longer-term responses to VEGF inhibition with drugs like pazopanib, though numbers remain small. Dr. Choy emphasizes that treatment changes provide hope, with even 20% response rates proving meaningful for responding patients in this rare disease setting.